Thermo Fisher Scientific and Cedars-Sinai have announced a collaboration to develop a pathway to precision medicine through the development of robust, reliable, and sensitive LC–MS-based workflows for clinical research applications.
Thermo Fisher Scientific (Waltham, Massachusetts, USA) and Cedars-Sinai (Los Angeles, California, USA) have announced a collaboration to develop a pathway to precision medicine through the development of robust, reliable, and sensitive liquid chromatography–mass spectrometry (LC–MS)-based workflows for clinical research applications.
“Thermo Fisher shares our vision for helping clinical research teams set new standards for excellence and innovation in patient care through precision medicine. The goal is to develop advanced
LC–MSâbased workflows for the untargeted screening and targeted quantitation of protein-based biomarkers for critical disease states, which hold the potential to benefit not only our own patients but also the wider clinical community,” said Jennifer Van Eyk, Ph.D., Principal Investigator for Research and Director of the Advanced Clinical Biosystems Institute in the Department of Biomedical Sciences at Cedars-Sinai.
For more information, please visit www.thermofisher.com/BeSure
Dispersive Liquid-Liquid Microextraction: A Review and Roundup of Green Sample Prep Advancements
May 15th 2024The still relatively new technique has distinct advantages, but a few of those benefits make it incompatible with some of the currently accepted principles of green sample preparation.
Analysis of Greenhouse Gases by Gas Chromatography
May 15th 2024This application note demonstrates the use of SCION's 8500GC system for the analysis of key greenhouse gases—carbon dioxide, methane, and nitrous oxide—in a single atmospheric air matrix. Highlighting the system's excellent sensitivity and repeatability, this method is crucial for understanding emission sources and combating climate change.